Lantern Pharma Inc (LTRN): Price-to-Revenue Ratio

Brandmark of Lantern (LTRN)

Lantern Pharma Inc. (LTRN) merges IT and medicine by utilizing the RADR AI system to match therapies with the genetics of lung cancer patients. The company has outsourced production and testing to third-party contractors to minimize costs. The company's P/S ratio reflects market expectations, where the level indicates the status of the parameter. The potential for business value growth is based on the B2B licensing of its predictive platform to other biopharma companies.

Price-to-Revenue Ratio: Lantern (LTRN) for 07/04/2022 - 11/14/2026

Analytical breakdowns for Lantern Pharma Inc. (LTRN)

- share price and consensus valuation forecast:
Price Performance Chart lanternpharma.com|LTRN - Price Target Chart
- stock exchange capitalization data:
Market Value Lantern|LTRN - Enterprise Value
- issuer book value statistics:
Book Value per Share Lantern Pharma|LTRN - Company Book Value|Capitalization to Book Value Ratio lanternpharma.com|LTRN - Cumulative Company Assets
- debt obligations and liquidity statistics:
Aggregate Debt to Capital Lantern Pharma Inc.|LTRN - Long-Term Debt to Capital|Current Liabilities to Capital lanternpharma.com|LTRN - Company Debts|Debt to Net Assets Ratio Lantern|LTRN - Company Long-Term Debt|Company Short-Term Indebtedness Lantern Pharma|Intermediate Coverage Ratio lanternpharma.com
- company profitability and valuation multiples indicators:
LTRN - Company Net Income|Forward Earnings Lantern Pharma Inc.|LTRN - P/E Multiple|Future Price to Earnings Multiple lanternpharma.com|LTRN - PEG Multiple|EV/EBITDA Multiple Lantern|LTRN - Profit before payment of interest, taxes and amortization|Earnings per share for the trailing year Lantern Pharma|LTRN - Earnings per share for the last twelve months|Year-over-year net earnings per share growth for the last 12 months lanternpharma.com|LTRN - Earnings growth in current year|Earnings growth forecast for next year Lantern Pharma Inc.
- total revenue and sales volume data:
LTRN - Company Sales|Company Future Revenue lanternpharma.com|LTRN - P/S Multiple|Market Cap to Expected Sales Ratio Lantern
Fundamental company analysis:Lantern Pharma Inc, LTRN
Brand item of Lantern

The P/S ratio depends directly on operating revenue, excluding the impact of accounting depreciation. This metric compares the market value of a business with its annual sales volume to determine the extent of the asset's overvaluation. For Lantern Pharma Inc. (LTRN), this indicator reflects the monetization of its AI platform through partnerships prior to the emergence of mass clinical data. Analyzing the price-to-sales chart allows for the timely detection of company overvaluation.

Competitors of Lantern Pharma Inc.

AVBP (ArriVent BioPharma, Inc.) - Market Capitalization-to-Revenue Ratio|Price-to-Revenue Ratio bioAffinity Technologies, Inc. BIAF|eEFFECTOR Therapeutics, Inc. - Price-to-Revenue Ratio